Circulating Tumor Cells Market Analysis, Size, Share, Growth To 2022 by Grand View Research, Inc.

Global circulating tumor cells market is anticipated to reach USD 11,552.3 million by 2022, according to a new report by Grand View Research, Inc. Rising developments in the field of biomedical engineering and biomedical imaging coupled with rise in patented research initiatives by the government is expected to drive this industry through the forecast period.
Introduction of novel technologies for enumeration of circulating tumor cells is anticipated to fuel growth in this sector through to 2022. Furthermore, increasing incidences of chronic oncology diseases that depend on the detection and analysis of CTCs, as it has enormous potential in the  real-time monitoring of cancer therapy, over the conventional methods such as imaging technologies and tumor tissue biopsy.
Additionally, application of CTC as biomarkers for drug discovery is a promising factor for growth in the coming years. Utilization of the circulating tumor cells in development of tumor specific biomarkers in order to optimize the selection of targeted therapies and assessment of better response to the therapy is expected to support in the projected growth of CTC market in the coming years.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market

North America CTC Enrichment Methods Market, By Technology, 2012-2022 (USD Million)

 

Further key findings from the study suggest:

• CTC enrichment accounted for the largest share of market revenue in 2014 and is expected to continue this dominance owing to high usage rates in oncology research establishments and high accuracy exhibited by this technology. 

• Microchips technology is anticipated to register substantial growth in the next seven years because of the introduction of cluster chip technology that enables capture of clusters of tumor cells for CTC quantitation. 

• Characteristic property of the cancer stem cells of self-renewal in replenishing the growing cancer is driving the attention of organizations and researchers in CTC cancer stem cell research segment thus accounting for the segment’s large share in revenue generation. 

• Application of alterations witnessed in the expression profiles of EMT-associated transcriptional regulators and their molecular targets as biomarkers in EMT study is expected to serve as an impetus for diagnosis of tumour recurrence consequently driving the segment with a double digit CAGR of over 10%. 

• North America dominated the market in 2014, with revenue estimation that accounted for over 45% of the global market. Presence of strong oncology research funding, refined healthcare infrastructure, growing incidence of cancer, favorable government initiatives with respect to R&D funding for clinical diagnostic products are factors attributive for larger revenue share. 

• Asia Pacific is anticipated to witness lucrative CAGR of over 16% as a result of infrastructure development in care centers coupled with increase in sales of CTC diagnostic tests. The need of new diagnosis methods for the growing cancer cases has gushed up research on new developments in developing economies of this region thus providing potential avenues for market growth. 

• Key participants of CTC industry include Canopus Biosciences, Clearbridge BioMedics, Fluxion Biosciences, Janssen Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell, Vitatex Inc., Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept Inc., Biofluidica, Creatv Microtech Inc., Ikonisys Inc., Epic Biosciences, Biocep Ltd., Greiner Bio-one GmbH, Sysmex Corporation, and CellTraffix Inc. 

• These market entities are involved in collaborations with hospitals and university based research institutes in order to gain access to target population and develop novel technologies for CTC enrichment & detection.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/biotechnology

Nerve Monitoring Devices Market Size Worth USD 1.9 Billion By 2022: Grand View Research, Inc.

Global nerve monitoring devices market is expected to reach USD 1.9 billion by 2022 according to a new study by Grand View Research Inc. Rising prevalence of neurological diseases, such as epilepsy, is a vital driver propelling market growth. Increasing geriatric population is another important driver responsible for growth of neuromonitoring devices, as these demographics are more prone to age-related neurodegenerative disorders.
Technological advancements such as wearable devices, which have better mobility and ability of round-the-clock monitoring, are expected to bolster the demand for these devices over the forecast period. Furthermore, large patient pool of neurological disorders is undiagnosed; hence, government is taking initiatives to promote early diagnosis, thereby increasing the demand for nerve monitoring devices.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/nerve-monitoring-devices-market

North America nerve monitoring device market, by technology, 2012-2022 (USD Million)

 

Further key findings from the study suggest:

• Electroencephalography was the largest technology segment in 2014, owing to its wide clinical utility and its ability to unfold brain activity within milliseconds providing higher accuracy
• On the contrary, electromyography is also expected to witness lucrative growth over the forecast period, attributed to rising prevalence of neuromuscular diseases such as muscular dystrophies and muscle rheumatism
• Monitors witnessed a rapid growth in demand, which resulted in the product accounting for the largest share in 2014. Ancillary products such as disposable sponge disks, abrasive gel, alcohol swabs, disposable filter, and electrode creams are expected to witness substantial growth over the next seven years. Increased usage and repeat purchases are likely to drive segment growth.
• North America dominated the regional nerve monitoring devices market with over 45.0% share in 2014. Advanced healthcare infrastructure coupled with growing disposable income is anticipated to drive growth of the market.
• Asia Pacific is expected to witness lucrative growth over the forecast period. Presence of high unmet needs and untapped opportunities in India and China are expected to open up new avenues for market players.
• Key players operating in this market include Medtronic Plc., NuVasive, Inc., Nihon Kohden, Natus Medical Inc., Langer Medical GmbH, Neurosign Surgical, Neurowave Systems, Cadwell Laboratories, Compumedics Limited, and Electrical Geodesics Inc. Key trends witnessed in this market include collaborations to gain competitive advantage, technological advancements, and new product launches.
• For instance, in January 2015, Natus Medical Inc. announced its entry in neurodiagnostics market through the acquisition of Global Neuro-Diagnostics, a provider of home-based EEG testing. This acquisition helped the company to widen the portfolio of nerve monitoring offerings. 

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

About Grand View Research

Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:

Sherry James

Corporate Sales Specialist, U.S.A.

Grand View Research, Inc.

United States           

Phone:  1-415-349-0058

Toll Free:  1-888-202-9519

Email:  sales@grandviewresearch.com 

Website:  Grand View Research                          

Blog Site: http://www.divog.org/

Disposable Medical Sensors Market Growth, Industry Trends To 2020 by Grand View Research, Inc.

Global disposable medical sensors market is expected to reach USD 7,543.1 million by 2020, according to a new study by Grand View Research, Inc. Increasing prevalence of HAIs (hospital acquired infections) and government initiatives aimed at reducing central-line associated bloodstream infections and surgical site infections in ward located and ICU patients are expected to serve the market as high impact rendering drivers. Introduction and subsequent rise in usage rates of novel technologies such as cancer tracking sensors, Hba1c sensors and MEMS pressure sensors is expected to boost future market growth.

Strip sensors dominated the overall product segment in terms of revenue and were valued at USD 1,800.2 million in 2013. Increasing prevalence of chronic diseases such as diabetes, cancer and cardiovascular disorders and the consequent rise in demand for diabetes and cancer biomarkers strip sensors are some factors accounting for its large share.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/disposable-medical-sensors-industry

Global disposable medical sensors market revenue, by product, 2013 - 2020, (USD Million)

 

Further key findings from the study suggest:

• Image sensors are expected to be a high growth segment over the forecast period owing to the introduction of technology advancements such as optic fiber technology; low power miniature CMOS image sensors and ZSRL image sensors. These sensors enable medical imaging and endoscopy systems to function with accuracy and therefore, help in effective diagnostic and therapeutic interventions.
• Disposable medical sensors based diagnostic applications dominated the overall market with revenue estimated at over 1,700.0 million in 2013. Increasing demand for point of care diagnoses such as i-stats, biosensors for the diagnosis and monitoring of glucose levels in emergency rooms is expected to drive the market during the forecast period.
• North America dominated the global market, accounting for over 35% of total revenue in 2013 on account of the presence of sophisticated healthcare infrastructure and growing R&D spending for the development of miniaturized and convenient medical sensors.
• Asia Pacific disposable medical sensors market is expected to grow at a CAGR of over 11.0% over the next six years, which is the highest among all regions. Increasing demand for home healthcare biosensors and improving healthcare infrastructure in emerging countries such as China and India are some factors contributing to its rapid growth.
• Some key players of disposable medical sensors include Honeywell International, Inc, Covidien Plc, STMicroelectronics, Given Imaging, Inc., GE Healthcare, Medtronic, Freescale Semiconductor, Inc., Philips Healthcare, Analog Devices, Smiths Medical, Measurement Specialties and Sensirion AG.

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/medical-devices

STD Diagnostics Market Hits $200.9 Billion By 2022: Grand View Research, Inc.

Global STD diagnostics market is expected to reach USD 200.9 billion by 2022 according to a new study by Grand View Research Inc. The rising geriatric population base, increasing global incidence of various STIs, rise in sedentary lifestyle adoption levels, and rising awareness & patient education are the driving forces for the STD diagnostics market growth over the forecast period.
Increasing number of people having multiple partners and low levels of infection awareness levels are the major drivers fueling industrial growth. Increasing demand for rapid and accurate diagnostic tests and presence of favorable government initiatives for STD testing in developing countries such as Brazil, India, and China are further estimated to boost market growth.

View summary of this report @ http://www.grandviewresearch.com/industry-analysis/diagnostic-testing-of-stds-market

Further key findings from the study suggest:

• Chlamydia testing accounted for over 34% of the market in 2014. Chlamydia testing for sexually active women aged below 25 years is strictly recommended by the U.S Preventive Services Task Force (PSTF). Syphilis testing is estimated to witness lucrative growth over the forecast period. It is anticipated to grow at a CAGR of 10% owing to increasing prevalence of syphilis infection globally.
• On the basis of test location, laboratory testing held the largest market share of over 63% in 2014 owing to the availability of cost effective diagnostic tests used for multiple STIs at a single location such as public health labs. Point of care on the other hand is anticipated to be the fastest growing segment over the forecast period owing to the owing to the introduction of CLIA waived tests
• Laboratory testing devices dominated the market in 2014 with revenue generation of over 67.0 billion. Immunochromatographic assays were most preferred devices for STD diagnosis in laboratory with revenue share of over 26%. Increasing technological advancements are estimated to enhance usage rates of thermal cyclers over the forecast period.
• Portable/bench top or rapid diagnostic kits are estimated to gain demand over the forecast period owing to features such as user-friendliness, increasing awareness pertaining to self testing, and fast results.
• North America held the largest share of the STD diagnostics market with revenue generation of over 32 billion in 2014. Introduction of technologically advanced diagnostics techniques such as immunochromatographic device by Chembio Diagnostics Systems Inc. is the major factor attributing for its largest market share.
• Asia Pacific region is estimated to witness significant growth over the forecast period owing to the presence of high amount of target population, rising awareness levels for STIs, and increasing government initiatives and rise in disposable income expenditure levels. Asia Pacific is expected to show double digit CAGR growth over the forecast period.
• Major companies of the STD diagnostics industry include Roche Holdings AG, Abbott Laboratories, Becton Dickinson and Company, Hologic Inc., Danaher Corporation, Affymetrix, BioMerieux, Cepheid Inc., Alere Inc., DiaSorin, and Orasure
• Licensing and partnership deal making activities in the molecular diagnostics sector are growing significantly in terms of value. New entrants such as life science research groups, financial investors, clinical laboratories, and medical technology players drive up the values. 

Browse All Reports of this category @ http://www.grandviewresearch.com/industry/clinical-diagnostics